ALLO Stock Price History and Quote Analysis Insights for Investors

NASDAQ : ALLO

Allogene Therapeutics, Inc.

$1.89

-0.13-6.44%

At Close 4:00 PM

$1.94

0.05+2.65%

After-Market 06:59 PM

63.69

BESG ScoreESG Rating

profile Key Stats Analyst Ratings Ownership Ratios Financials Dividend & splits Sentiment Forecast

Stock Price Today

Allogene Therapeutics, Inc. (ALLO) stock declined over -6.44%, trading at $1.89 on NASDAQ, down from the previous close of $2.02. The stock opened at $2.03, fluctuating between $1.83 and $2.03 in the recent session.

Stock Snapshot

2.02

Prev. Close

2.03

Open

396.28M

Market Cap

209.67M

Number of Shares

1.8306

Day Low

2.03

Day High

-1.22

P/E Ratio

68.02%

Free Float in %

-1.55

EPS (TTM)

3.04

Book Value

-1.42

Cash Flow per Share

3.48M

Volume

Stock Price History Chart

Date	Open	High	Low	Close	Volume
Dec 13, 2024	2.03	2.03	1.83	1.89	3.51M
Dec 12, 2024	2.13	2.13	2.00	2.02	2.73M
Dec 11, 2024	2.17	2.19	2.08	2.15	2.18M
Dec 10, 2024	2.25	2.31	2.17	2.19	1.88M
Dec 09, 2024	2.21	2.35	2.16	2.27	2.68M
Dec 06, 2024	2.16	2.29	2.13	2.19	2.65M
Dec 05, 2024	2.18	2.22	2.10	2.14	1.87M
Dec 04, 2024	2.33	2.37	2.25	2.26	1.36M
Dec 03, 2024	2.52	2.52	2.29	2.32	2.28M
Dec 02, 2024	2.48	2.59	2.48	2.55	2.06M
Nov 29, 2024	2.50	2.54	2.45	2.48	1.53M
Nov 27, 2024	2.53	2.62	2.48	2.50	2.26M
Nov 26, 2024	2.51	2.77	2.44	2.52	5.29M
Nov 25, 2024	2.26	2.36	2.23	2.28	3.96M
Nov 22, 2024	2.12	2.23	2.09	2.21	1.46M
Nov 21, 2024	2.06	2.14	2.01	2.11	1.86M
Nov 20, 2024	2.11	2.14	1.99	2.05	2.45M
Nov 19, 2024	2.13	2.14	2.04	2.12	2.81M
Nov 18, 2024	2.30	2.32	2.14	2.15	2.92M
Nov 15, 2024	2.52	2.52	2.26	2.27	3.09M

Contact Details

South San Francisco, CA 94080

United States

Website: https://www.allogene.comContact: 650 457 2700

About Company

Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell ALL. The company also develops ALLO-501, an anti-CD19 allogeneic CAR T cell product candidate that is in Phase I clinical trial for the treatment of R/R non-Hodgkin lymphoma; and ALLO-501A, which is in Phase I/II clinical trial for the treatment R/R large B-cell lymphoma or transformed follicular lymphoma. In addition, it is developing ALLO-715, an allogeneic CAR T cell product candidate that is in a Phase I clinical trial for treating R/R multiple myeloma; ALLO-605, an allogeneic CAR T cell product candidate for the treatment of multiple myeloma; ALLO-647, an anti-CD52 monoclonal antibody; CD70 to treat renal cell cancer; ALLO-819, an allogeneic CAR T cell product candidates for the treatment of acute myeloid leukemia; and DLL3 for the treatment of small cell lung cancer and other aggressive neuroendocrine tumors. The company has license and collaboration agreements with Pfizer Inc.; Servier; Cellectis S.A.; and Notch Therapeutics Inc., as well as clinical trial collaboration agreement with SpringWorks Therapeutics, Inc. It also has a strategic collaboration agreement with The University of Texas MD Anderson Cancer Center for the preclinical and clinical investigation of allogeneic CAR T cell product candidates. The company was incorporated in 2017 and is headquartered in South San Francisco, California.

Frequently Asked Questions

What is the current Allogene Therapeutics, Inc. (ALLO) stock price?

Allogene Therapeutics, Inc. (NASDAQ: ALLO) stock price is $1.89 in the last trading session. During the trading session, ALLO stock reached the peak price of $2.03 while $1.83 was the lowest point it dropped to. The percentage change in ALLO stock occurred in the recent session was -6.44% while the dollar amount for the price change in ALLO stock was -$0.13.

ALLO's industry and sector of operation?

The NASDAQ listed ALLO is part of Biotechnology industry that operates in the broader Healthcare sector. Allogene Therapeutics, Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.

Who are the executives of ALLO?

Mr. Arun Balakumaran M.D., Ph.D.
Chief Medical Officer
Dr. Alison Moore Ph.D.
Chief Technical Officer
Dr. Eric Thomas Schmidt Ph.D.
Executive Vice President & Chief Financial Officer
Mr. Veer Bhavnagri
Gen. Counsel & Compliance Officer
Dr. Arie S. Belldegrun F.A.C.S., FACS, M.D.
Co-Founder & Executive Chairman
Dr. David D. Chang M.D., Ph.D.
Co-Founder, Pres, Chief Executive Officer & Director
Mr. Joshua A. Kazam
Co-Founder & Director
Mr. Timothy L. Moore Ph.D.
Executive Vice President & Chief Technical Officer
Ms. Barbra Sasu
Chief Scientific Officer
Mr. Stephen Cheng
Chief Information Officer
Ms. Lillian Smith
Interim Gen. Counsel & Compliance Officer
Ms. Christine Cassiano
Chief Communications Officer
Ms. Susan R. Lundeen
Chief People Officer
Ms. Diane Hagerty
Senior Vice President of Quality
Dr. Rafael G. Amado M.D.
Pres and Head of Global Oncology R&D

How ALLO did perform over past 52-week?

ALLO's closing price is 3.25% higher than its 52-week low of $1.83 where as its distance from 52-week high of $5.78 is -67.3%.

How many employees does ALLO have?

Number of ALLO employees currently stands at 232.

Link for ALLO official website?

Official Website of ALLO is: https://www.allogene.com

How do I contact ALLO?

ALLO could be contacted at phone 650 457 2700 and can also be accessed through its website. ALLO operates from 210 East Grand Avenue, South San Francisco, CA 94080, United States.

How many shares of ALLO are traded daily?

ALLO stock volume for the day was 3.48M shares. The average number of ALLO shares traded daily for last 3 months was 2.26M.

What is the market cap of ALLO currently?

The market value of ALLO currently stands at $396.28M with its latest stock price at $1.89 and 209.67M of its shares outstanding.

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

About

Home About Meet The Team Contact Us Privacy Policy Newsletter

Stock Price Today

Stock Snapshot

2.02

Prev. Close

2.03

Open

396.28M

Market Cap

209.67M

Number of Shares

1.8306

Day Low

2.03

Day High

-1.22

P/E Ratio

68.02%

Free Float in %

-1.55

EPS (TTM)

3.04

Book Value

-1.42

Cash Flow per Share

3.48M

Volume

Stock Price History Chart

Date	Open	High	Low	Close	Volume
Dec 13, 2024	2.03	2.03	1.83	1.89	3.51M
Dec 12, 2024	2.13	2.13	2.00	2.02	2.73M
Dec 11, 2024	2.17	2.19	2.08	2.15	2.18M
Dec 10, 2024	2.25	2.31	2.17	2.19	1.88M
Dec 09, 2024	2.21	2.35	2.16	2.27	2.68M
Dec 06, 2024	2.16	2.29	2.13	2.19	2.65M
Dec 05, 2024	2.18	2.22	2.10	2.14	1.87M
Dec 04, 2024	2.33	2.37	2.25	2.26	1.36M
Dec 03, 2024	2.52	2.52	2.29	2.32	2.28M
Dec 02, 2024	2.48	2.59	2.48	2.55	2.06M
Nov 29, 2024	2.50	2.54	2.45	2.48	1.53M
Nov 27, 2024	2.53	2.62	2.48	2.50	2.26M
Nov 26, 2024	2.51	2.77	2.44	2.52	5.29M
Nov 25, 2024	2.26	2.36	2.23	2.28	3.96M
Nov 22, 2024	2.12	2.23	2.09	2.21	1.46M
Nov 21, 2024	2.06	2.14	2.01	2.11	1.86M
Nov 20, 2024	2.11	2.14	1.99	2.05	2.45M
Nov 19, 2024	2.13	2.14	2.04	2.12	2.81M
Nov 18, 2024	2.30	2.32	2.14	2.15	2.92M
Nov 15, 2024	2.52	2.52	2.26	2.27	3.09M

Contact Details

South San Francisco, CA 94080

United States

Website: https://www.allogene.comContact: 650 457 2700

About Company

Frequently Asked Questions

What is the current Allogene Therapeutics, Inc. (ALLO) stock price?

ALLO's industry and sector of operation?

Who are the executives of ALLO?

How ALLO did perform over past 52-week?

ALLO's closing price is 3.25% higher than its 52-week low of $1.83 where as its distance from 52-week high of $5.78 is -67.3%.

How many employees does ALLO have?

Number of ALLO employees currently stands at 232.

Link for ALLO official website?

Official Website of ALLO is: https://www.allogene.com

How do I contact ALLO?

ALLO could be contacted at phone 650 457 2700 and can also be accessed through its website. ALLO operates from 210 East Grand Avenue, South San Francisco, CA 94080, United States.

How many shares of ALLO are traded daily?

ALLO stock volume for the day was 3.48M shares. The average number of ALLO shares traded daily for last 3 months was 2.26M.

What is the market cap of ALLO currently?

The market value of ALLO currently stands at $396.28M with its latest stock price at $1.89 and 209.67M of its shares outstanding.

Employees	232
Beta	0.84
Sales or Revenue	$95.00K
5Y Sales Change%	0%
Fiscal Year Ends	December
Sector	Healthcare
Industry	Biotechnology

Employees	232
Beta	0.84
Sales or Revenue	$95.00K
5Y Sales Change%	0%
Fiscal Year Ends	December
Sector	Healthcare
Industry	Biotechnology

ALLO Stock Price History and Quote Analysis Insights for Investors

Allogene Therapeutics, Inc.

Stock Price Today

Stock Snapshot

Stock Price History Chart

Contact Details

About Company

Company Information

Frequently Asked Questions

Stock Price Today

Stock Snapshot

Stock Price History Chart

Contact Details

About Company

Company Information

Frequently Asked Questions